metricas
covid
Buscar en
Gastroenterología y Hepatología
Toda la web
Inicio Gastroenterología y Hepatología Hepatitis autoinmune y anticuerpos anti-Ro positivos. ¿Alguna relación?
Información de la revista
Vol. 26. Núm. 8.
Páginas 475-479 (enero 2003)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 26. Núm. 8.
Páginas 475-479 (enero 2003)
Acceso a texto completo
Hepatitis autoinmune y anticuerpos anti-Ro positivos. ¿Alguna relación?
Autoimmune hepatitis and anti-ro antibodies. is there a link?
Visitas
20357
F.Devesa i Jordàa,
Autor para correspondencia
devesa_fra@gva.es

Correspondencia: Dr. F. Devesa i Jordà. Hospital Francesc de Borja. Passeig de les Germanies, 71. 46700 Gandia. Valencia. España.
, J.Ferrando Ginestara, M.Bustamante Baléna, J.Ortuño Cortésa, A.Borghol Hariria, J.A.Ramos Ñíguezb, A.Jiménez Sánchezb, S.Mery Ramsc, S.Rull Segurad
a Unidad de Aparato Digestivo. Servicio de Medicina Interna. Hospital Clínic Universitari. Valencia. España
b Servicio de Anatomía Patológica. Hospital Clínic Universitari. Valencia. España
c Laboratorio de Microbiología. Hospital Clínic Universitari. Valencia. España
d Jefe del Servicio de Medicina Interna. Hospital Francesc de Borja. Gandia. Valencia. Españ
Este artículo ha recibido
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas
Resumen

:Los anticuerpos antinucleares (AAN) son considerados como marcadores de enfermedad autoinmune. Se conocen distintas reactividades específicas de los AAN, entre las que se encuentra el complejo Ro (SS-A). Aunque la presencia de anticuerpos anti-Ro es ampliamente conocida en conectivopatías sistémicas, como el lupus eritematoso o el síndrome de Sjögren, hay pocos estudios que intenten relacionar esta partícula con la hepatitis autoinmune (HAI). Presentamos un caso de HAI de curso agudo, en una mujer de 55 años, con anti-Ro positivo de 60 kD. El antígeno Ro (SS-A) es una ribonucleoproteína compleja, cuya estructura está sometida a debate y de la que se conocen dos fracciones fundamentales de 52 y 60 kD, respectivamente. En la revisión efectuada se encuentran unas frecuencias entre las HAI del 21 al 34% para anti-Ro de 52 kD, y del 9 al 13,6% para anti-Ro de 60 kD. A pesar de no haberse demostrado ninguna relación de este complejo con mecanismos etiopatogénicos o con patrones clínicos de las HAI, se proponen investigaciones multicéntricas con series amplias antes de descartar definitivamente la implicación de los anticuerpos anti-Ro en estas enfermedades.

Antinuclear antibodies (ANA) are considered to be markers of autoimmune disease. Several specific reactivities of ANA are known, among them the Ro (SS-a) complex. Although the presence of anti-Ro antibodies is widely known in systemic connective tissue diseases such as lupus erythematous or Sjögren's syndrome, few studies have attempted to link this finding with autoimmune hepatitis (AIH). We present a case of acute AIH in a 55-year-old woman who tested positive for anti-Ro 60 kD antibodies. The Ro (SS-A) antigen is a complex ribonucleoprotein whose structure is still the subject of debate. Two fractions, of 50 and 60 kD, have been identified. A review of the literature revealed frequencies of 21-34% for anti-Ro 52 kD and of 9-13-6% for anti-Ro 60 kD in AIH. Although no relationship has been demonstrated between this complex and the etiopathogenic mechanisms or clinical patterns of AIH, we propose that multicenter investigations with large series should be performed before the possible involvement of anti-Ro antibodies in these diseases is definitively ruled out.

El Texto completo está disponible en PDF
Bibliografía
[1.]
G.V. Gregorio, E.T. Davis, G. Mieli-Vergani, D. Vergani.
Significance of extractable nuclear antigens in childhood autoimmune liver disease.
Clin Exp Immunol, 102 (1995), pp. 308-313
[2.]
S. Parveen, S.A. Morshed, K. Arima, M. Nishioka, A.J. Czaja, W.C.h. Chow, et al.
Antibodies to Ro/La, Cenp-B and snRNPs antigens in autoimmune hepatitis of North America versus Asia. Patterns of immunofluorescence, ELISA reactivities and HLA association.
Dig Dis Sci, 43 (1998), pp. 1322-1331
[3.]
F. Álvarez, P.A. Berg, F.B. Bianchi, L. Bianchi, A.K. Burroughs, E.L. Cancado, et al.
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.
J Hepatol, 31 (1999), pp. 929-938
[4.]
Y. Sherer, Y. Shoenfeld.
The idiotypic network in antinuclearantibody-associated diseases.
Int Arch Allergy Immunol, 123 (2000), pp. 10-15
[5.]
G. Clark, M. Reichlin, T.B. Tomasi.
Characteritzacion of a soluble cytoplasmic antigen reactive with sera from patients with systemic lupus erythematosus.
J Immunol, 102 (1969), pp. 117-130
[6.]
M. Mattioli, M. Reichlin.
Heterogeneity of RNA protein antigens reactive with sera of patients.
Arthritis Rheum, 17 (1974), pp. 421-429
[7.]
M.A. Alspaugh, E.M. Tan.
Antibodies to cellular antigens in Sjögren's syndrome.
J Clin Invest, 55 (1975), pp. 1067-1073
[8.]
J. Sibilia.
Ro (SS-A) and anti-Ro (SS-A): an update.
Rev Rheum Engl Ed, 65 (1998), pp. 45-57
[9.]
R.H. Scofield, A.D. Farris, A.C. Horsfall, J.B. Harley.
Fine specificity of the autoimmune response to the Ro/SSA and La/SSB ribonucleoproteins.
[10.]
C. Zimmermann, J.S. Smolen, W. Graninger, P. Petera, G. Fabini, W. Hassfeld, et al.
Fine Specificity of anti-Ro (SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus.
J Rheumatol, 23 (1996), pp. 1897-1903
[11.]
E. Simmons-O'Brien, S. Chen, R. Watson, C. Antoni, M. Petri, M. Hochberg, et al.
One hundred anti-Ro (SS-A) antibody positive patients: a 10-year folow-up.
Medicine (Baltimore), 74 (1995), pp. 109-130
[12.]
R. Peek, G.J.M. Prujin, A.J.W. Van Der Kemp, W.J. Van Venrooij.
Subcellular distribution of Ro ribonucleoprotein complexes and their constituents.
J Cell Sci, 106 (1993), pp. 929-935
[13.]
F.H.M. Simons, S.A. Rutges, W.J. Vanvenrooij.
Prujin GJM. The interactions with Ro 60 and La differentially affect nuclear export of hY1 RNA.
RNA, 2 (1996), pp. 264-273
[14.]
A. Kelekar, M.R. Saitta, J.D. Keene.
Molecular composition of Ro small ribonucleoprotein complexes in human cells. Intracellular localization of the 60-and 52-kD proteins.
J Clin Invest, 93 (1994), pp. 1637-1644
[15.]
E. Alexander, J.P. Buyon, T.T. Provost, T. Guarnieri.
Anti-Ro/SSA antibodies in the pathophyisiology of congenital heart block in neonatal lupus syndrome, an experimental model. In vitro electrophysiologic and immunocytochemical studies.
Arthritis Rheum, 35 (1992), pp. 176-189
[16.]
S. Garcia, J.H. Nascimiento, E. Bonfa, R. Levy, S.F. Oliveira, A.V. Tavares, et al.
Cellular mechanisms of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts.
J Clin Invest, 93 (1994), pp. 718-724
[17.]
H. Kita, I.R. Mackay, J. Van the Water, M.E. Gershwin.
The lymphoid liver: considerations on pathways to autoimmune injury.
Gastroenterology, 120 (2001), pp. 1485-1501
[18.]
U. Wolina, H. Beensen, L. Kittler, H. Schaarschmidt, B. Knopf.
PUVA treatment of human cultured fibroblasts from psoriatic skin enhances the binding of antibodies to SSA (Ro).
Dermatol Res, 279 (1987), pp. 206-208
[19.]
J. Zhu.
Cytomegalovirus infection induces expression of 60 kD/Ro antigen on human keratinocytes.
Lupus, 4 (1995), pp. 396-406
[20.]
F. Furukawa, M.B. Lyons, L.A. Lee, S.N. Coulter, D.A. Norris.
Estradiol enhances binding to cultured human keratinocytes of antibodies specific for SS-A/Ro and SS-B/La. Another possible mechanism for estradiol influence of lupus erythematosus.
J Immunol, 141 (1988), pp. 1480-1488
[21.]
Smeenk RJT.
RO/SS-A and La/SS-B: Autoantigens in Sjögren's syndrome?.
Clin Rheumatol, 14 (1995), pp. 11-16
[22.]
P. Bouffard, M.A. Laniel, G. Boire.
Anti-Ro (SSA) antibodies: clinical significance and biological relevance.
J Rheumatol, 23 (1996), pp. 1838-1841
[23.]
L.A. Lee, C.E. Harmon, J.C. Huff, D.A. Norris, W.L. Weston.
The demonstration of SS-A/Ro antigen in human fetal tissues and in neonatal and adult skin.
J Invest Dermatol, 85 (1985), pp. 143-146
[24.]
T. Dorner, E. Feis, C. Held, K. Conrad, G.R. Burmester, F. Hiepe.
Differential recognition of the 52-kD Ro (SS-A) antigen by sera from patients with primary Sjögren's syndrome.
Hepatology, 24 (1996), pp. 1404-1407
[25.]
M.J. Chou, S.L. Lee, T.Y. Chen, G.J. Tsay.
Specificity of antinuclear antibodies in primary biliary cirrhosis.
Ann Rheum Dis, 54 (1995), pp. 148-151
[26.]
A.J. Czaja, M. Nishioka, S.A. Morshed, T. Hachiya.
Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis.
Gastroenterology, 107 (1994), pp. 200-207
[27.]
E.L. Krawitt.
Autoimmune hepatitis.
N Eng J Med, 334 (1996), pp. 897-903
[28.]
M. Bruguera, L.l. Caballería, A. Parés, J. Rodés.
Hepatitis autoinmune. Características clínicas y respuesta al tratamiento de una serie de 49 pacientes españoles.
Gastroenterol Hepatol, 21 (1998), pp. 375-381
[29.]
R.H. Scofield, J.B. Harley.
Autoantigenicity of Ro/SSA antigen is related to a nucleocapsid protein of vesicular stomatitis virus.
Proc Natl Acad Sci, 88 (1991), pp. 3343-3347
[30.]
R.H. Scofield, W.D. Dickey, K.W. Jackson, J.A. James, J.B. Harley.
A common autoepitope near the carboxyl terminus of the 60-kD Ro ribonucleoprotein: sequence similarity with a viral protein.
J Clin Immunol, 11 (1991), pp. 378-388
[31.]
J.B. Harley, M. Reichlin, F.C. Arnett, E.L. Alexander, W.B. Bias, T.T. Provost.
Gene interaction at HLA-DQ enhances autoantibody production in primary Sjögren's syndrome.
Science, 232 (1986), pp. 1145-1147
[32.]
M.P. Manns, C.P. Strassburg.
Autoimmune hepatitis: clinical challenges.
Gastroenterology, 120 (2001), pp. 1502-1517
[33.]
A.J. Czaja, H.A. Homburger.
Autoantibodies in liver disease.
Gastroenterology, 120 (2001), pp. 239-249
[34.]
A.J. Czaja, D.K. Freese.
Diagnosis and treatment of autoimmune hepatitis.
Hepatology, 36 (2002), pp. 479-497
[35.]
M. García, M. Ramos, R. Cervera, M. Ingelmo.
Mecanismos inmunopatogénicos de los anticuerpos.
Autoanticuerpos en la práctica clínica, pp. 37-50
[36.]
W.Z. Mehal, F. Azzaroli, N. Crispe.
Immunology of the healthy liver: old questions and new insigths.
Gastroenterology, 120 (2001), pp. 250-260
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos